HIV-Related Cancers

Posted on June 18, 2018

Providers caring for persons living with HIV (PLWH) should be aware of the HIV-associated cancers and potential interactions during treatment. Two recent New England Journal of Medicine articles, HIV-Associated Cancers and Related Diseases [N Engl J Med 378;11, March 15, 2018] and a correspondence article of the same title HIV-Associated Cancers and Related Diseases (Correspondence) [N Engl J Med 378;22 May 31, 2018], provide a good review/overview/etiology of cancers to be aware of. The correspondence article specifically addresses drug interactions to be aware of when caring for PLWH during cancer treatment.   

Webinar Recording: HIV Testing Technologies – Choosing an HIV Test

Posted on February 20, 2018

APLA-Shared ActionHD produced the webinar “HIV Testing Technologies: Choosing an HIV Test,” presented by Dr. Bernard M. Branson, a leading expert in the area of HIV testing. The webinar described general principles of HIV tests, provided an overview of how tests operate, addressed any limitations and misconceptions of HIV tests currently available, and discussed how the various tests differ. There was also a discussion on practical considerations for health departments to consider when deciding which HIV-test to utilize.

To view the webinar, visit website archive page [UMKC].

New FREE Continuing Education from MMWR and Medscape: HIV Testing and Diagnosis Delays

Posted on January 30, 2018

CDC’s MMWR and Medscape are proud to introduce a new FREE continuing education (CE) activity that describes diagnosis delays among persons infected with HIV: Vital Signs: Human Immunodeficiency Virus Testing and Diagnosis Delays — United States.

This activity is intended for infectious disease clinicians, family medicine specialists, internists, nurses, pharmacists, public health officials, and other clinicians caring for patients with or at risk for HIV infection.

Upon completion of this activity, participants will be able to:

  1. Describe diagnosis delay among persons infected with HIV, based on an analysis of data from the Centers for Disease Control and Prevention’s National HIV Surveillance System, and missed opportunities for HIV testing, based on CDC’s National HIV Behavioral Surveillance.
  2. Identify the proportions of persons in various high-risk populations who tested for HIV in the past 12 months.
  3. Determine the clinical and public health implications of these findings regarding HIV testing, missed opportunities for testing, and diagnosis delay among persons infected with HIV.

To access this FREE MMWR / Medscape CE activity visit the CDC website. If you are not a registered user on Medscape, please register for free or login without a password and get unlimited access to all continuing education activities and other Medscape features.

FDA Approves First Two-Drug Regimen For Certain Patients With HIV

Posted on November 27, 2017

The U.S. Food and Drug Administration today approved Juluca, the first complete treatment regimen containing only two drugs to treat certain adults with human immunodeficiency virus type 1 (HIV-1) instead of three or more drugs included in standard HIV treatment. Juluca is a fixed-dose tablet containing two previously approved drugs (dolutegravir and rilpivirine) to treat adults with HIV-1 infections whose virus is currently suppressed on a stable regimen for at least six months, with no history of treatment failure and no known substitutions associated with resistance to the individual components of Juluca.

Learn more [The Forum]

Advancing PrEP in Practice: Practical Strategies for Everyday Challenges

Posted on September 22, 2017

This activity is intended for primary care physicians, ID/HIV specialists, and public health and preventive medicine specialists.

The goal of this activity is to improve recognition among primary care providers of patients who could benefit from human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) medications.

Upon completion of this activity, participants will have greater competence related to:

  • Identifying patients who are candidates for PrEP
  • Clinical and laboratory assessments that should be made before the initiation of PrEP
  • Monitoring of patients who are receiving PrEP
  • Use of PrEP in women who are pregnant or considering becoming pregnant

CME credits are available for this program.

Visit the program website to learn more [Medscape].

Health Advisory: Rapidly Growing Clusters of Ongoing HIV Transmission in Texas

Posted on August 16, 2017

DSHS encourages Texas healthcare providers to enhance efforts to prevent, diagnose and treat HIV in the wake of 16 rapidly growing clusters of HIV infections in the state. Laboratory analysis of these infections indicates sustained transmission of genetically similar types of HIV… Learn more (PDF : 327 kb)

PrEP regimens containing Selzentry safe, well-tolerated compared with Truvada

Posted on November 15, 2016

Pre-exposure prophylaxis regimens containing Selzentry were generally safe and well-tolerated compared with Truvada, the standard-of-care PrEP drug, according to the results of a phase 2 trial.

Roy M. Gulick, MD, MPH, professor of medicine and chief of the division of infectious diseases at Weill Cornell Medicine, and colleagues studied four PrEP regimens in at-risk HIV-uninfected men and transgender women who have sex with men and concluded that regimens containing Selzentry (maraviroc, ViiV Heathcare; MVC) “may warrant further study for PrEP,” they wrote in The Journal of Infectious Diseases.


Texas Medicine provides insight on PrEP for women

Posted on November 10, 2016

Texas Medicine provides talking points and information on offering PrEP to women at risk for contracting HIV. How do you know your patients are at risk for HIV? Ask tough questions. Read more [TMA]

PrEP uptake low among women at risk

Posted on October 24, 2016

According to a retrospective study of data, women at risk for HIV are not participating in PrEP  treatment. The researchers recommend targeted intervention plans to increase use among people most likely to benefit from it.  Read the study [].

AETC offers Hepatitis webinar series and online curriculum

Posted on October 13, 2016

The AIDS Education and Training Center (AETC) Southeast has announced a webinar series for October focused on Hepatitis C.  To view the webinars, check their calendar.  They also have an online curriculum for Medical Case Management.  For more information, view their introductory video [SEAETC].

ED study demonstrates value of Fourth-Generation HIV testing

Posted on September 13, 2016

A recent study of emergency department patients demonstrates the value of fourth generation HIV screenings. Over 22,000 people were tested for HIV using an antigen/antibody combination HIV assay test. Physicians delivered positive test results to 78 patients with the assistance of a linkage-to-care specialist. Of particular importance, 18 (23%) of these were acute infections. Acute infections are not  likely to be found using previous testing methods. An abstract and podcast [] are available at no cost.

Despite low uptake, more than half of MSM willing to take PrEP

Posted on August 29, 2016

According to a recent study of 20 cities, more than 60% of men who have sex with men (MSM) are interested in pre-exposure prophylaxis (PrEP). Currently less than four percent participate in the therapy. Black and white respondents did not differ in their interest in taking PrEP. However, currently more white males take PrEP. Clinicians are urged to consider factors such as HIV incidence and prevalence in subgroups when discussing PrEP with patients.

New study finds efficacy for ART/PrEP combo

Posted on August 26, 2016

A recent study [] has demonstrated support for the use of a combination of ART and PrEP therapy in serodiscordant heterosexual couples in Kenya and Uganda. Heterosexual contact is the primary mode of transmission in Africa and the implementation of this approach could drastically reduce HIV.

PrEP Can Cut New HIV Infections by One-third in Next Decade

Posted on August 15, 2016

According to a new modeling study, HIV incidence could be reduced by one third if almost half of eligible men who have sex with men participated in PrEP. Treatment adherence is an important aspect in the model. Targeting individuals at a substantial risk for transmission is also key. Read more [].

Nanoparticles Containing Dolutegravir Demonstrate Efficacy for PrEP Delivery

Posted on August 15, 2016

The need for new options in PrEP that are cost-effective and efficacious is driving innovation in the field of nanotechnology. For more on a possible advancement in vaginal microbicides, read this article []. 

What Happens When You Test Everyone In The ER For HIV?

Posted on May 19, 2016

More than 1.2 million people in the United States are living with HIV — and one in eight of them don’t know they have the infection, according to the Department of Health and Human Services.

Here in the Phoenix area, one hospital is trying to find those people, diagnose them — and get them into treatment.

Maricopa Integrated Health Services has been the home of TESTAZ, a program that brings routine testing for HIV into their Emergency Department, since 2011.

Source: KJZZ Arizona Public Radio

ART and PrEP can fight AIDS globally

Posted on March 23, 2016

Anthony Fauci summarizes recent research on the timing of ART and the efficacy of PrEP for prevention in this New England Journal of Medicine article. He calls for the resources and political will to increase HIV testing and treatment globally.

Learn More about ART Program [NEJM]

Updating the HIV – Testing Guideline – A Modest Change with Major Consequences

Posted on January 12, 2016

The U.S. Preventative Services Task Force (USPSTF) recently released a draft statement assigning a grade A recommendation to screening for human immunodeficiency virus (HIV) in the general population 15 to 65 years of age.

The proposed guidelines cite an updated systematic evidence review of the benefits and potential harms of HIV screening.  Since the previous evidence review was published in 2005, new studies have shown that antiretroviral therapy can reduce transmission by HIV – infected persons and that earlier initiation of such therapy can reduce morbidity and mortality and improve quality of life.

Source: The New England Journal of Medicine  

TestTexas HIV Coalition logo

Approximately 18,000 Texans are unaware of their HIV infection.

Knowledge is power. Learning one’s positive serostatus is the first step for newly diagnosed HIV patients to get linked to care and treated early in the disease process with the potential to have a nearly normal lifespan.
- C. Everett Koop, Former Surgeon General of the United States

Last updated April 29, 2020